DDC Enterprise Announces First Half 2025 Earnings Conference Call for September 4, 2025

DDC Enterprise Limited (NYSE: DDC) ("DDC" or the " Company "), an Asian consumer-first company at the forefront of corporate bitcoin acquisition and treasury management, today announced it will report its financial results for the first half of 2025 on Thursday, September 4, 2025 at 8:00 AM EDT. DDC will cover the financial results for the six months ended June 30, 2025, as well as provide a business update.

DDC will release its earnings before the call at approximately 7:00 AM EDT on September 4, 2025. A copy of the earnings release will be available on the Company's Investor Relations website at ir.DDC.xyz.

Conference Call Information:

  • Date : September 4, 2025
  • Time : 8:00 AM EDT
  • Participant Call Links :

Participants wishing to join the conference call by phone should register using the Participant Call Registration link provided above. After completing the registration, the participants will receive an email with the necessary details to access the call, including the dial-in number, passcode, and PIN. To ensure a timely start, the Company encourages all callers to connect 5 minutes before the scheduled time.

A live and archived webcast of the conference call will be available on the Investors section of DDC's website at ir.DDC.xyz.

About DDC Enterprise Limited (NYSE: DDC)

DDC Enterprise Limited (NYSE: DDC) is spearheading the corporate Bitcoin treasury revolution while maintaining its foundation as a leading global Asian food platform. The Company has strategically positioned Bitcoin as a core reserve asset, executing a bold and accelerating accumulation strategy. While continuing to grow its portfolio of culinary brands, DDC is now at the vanguard of public companies integrating Bitcoin into their financial architecture.

Media & Investor Contacts

Investor Relations
Orange Group | Yujia Zhai
ddc@orangegroupadvisors.com

Press and Media
pr@ddc.xyz

News Provided by Business Wire via QuoteMedia

DDC
The Conversation (0)
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors

NUV-1511 is the first clinical candidate from the company's novel drug-drug conjugate platform Company anticipates initiating a Phase 1/2 clinical study of NUV-1511 in 1H 2024 Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by... Keep Reading...
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

Phase 1 monotherapy study of NUV-868 and Phase 1b study of NUV-868 in combination with olaparib or enzalutamide are ongoing Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash equivalents, and marketable securities... Keep Reading...
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Announced formation of oncology-focused... Keep Reading...
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board

Scientific Advisory Board members bring significant global expertise in oncology drug and clinical development Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today... Keep Reading...
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update

Enrollment ongoing in the Phase 1b study of NUV-868 in combination with olaparib or enzalutamide Enrollment ongoing in the Phase 1 monotherapy study of NUV-868 Expect to submit an IND for first Drug-Drug Conjugate (DDC) clinical candidate by year end 2023 Strong balance sheet with cash, cash... Keep Reading...
Auto Finance Veteran and Former Tesla National Lease Partner Launches AmeriTrust Financial to Fill Used-Car Leasing Gap

Auto Finance Veteran and Former Tesla National Lease Partner Launches AmeriTrust Financial to Fill Used-Car Leasing Gap

AmeriTrust's platform is the first to deliver side-by-side loan and lease decisions from a single retail application, with live-inventory calculators that enable lower payments on shorter terms. AmeriTrust Financial, an independent automotive finance company, today announced the launch of a... Keep Reading...
AmeriTrust Announces Closing of Second and Final Tranche of Brokered Offering

AmeriTrust Announces Closing of Second and Final Tranche of Brokered Offering

Not for distribution to U.S. Newswire Services or Dissemination in the United States TORONTO, ONTARIO / ACCESS Newswire / January 15, 2026 / AmeriTrust Financial Technologies Inc. (TSXV:AMT)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform targeting... Keep Reading...
AmeriTrust Announces Closing First Tranche of Brokered Offering for $36,187,200

AmeriTrust Announces Closing First Tranche of Brokered Offering for $36,187,200

Not for distribution to U.S. Newswire Services or Dissemination in the United States TORONTO, ONTARIO / ACCESS Newswire / December 23, 2025 / AmeriTrust Financial Technologies Inc. (TSXV:AMT)(OTCQB:AMTFF)(Frankfurt:1ZVA) ("AmeriTrust", "AMT" or the "Company"), a fintech platform targeting... Keep Reading...

Keith Prusek and Hugh Rabb Join Evercore as Senior Managing Directors in the Transportation Investment Banking Group

Evercore announced today that Keith Prusek and Hugh Rabb have joined the firm as senior managing directors in its transportation investment banking group. Both will be based in Richmond, Virginia, where Evercore has opened a new office as part of its ongoing initiative to further expand its... Keep Reading...

Interactive Chart

Latest Press Releases

Related News